^
Association details:
| Biomarker: | PTEN H93D |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Excerpt:
Patient 1 had a PTEN H93D missense mutation in the pre-treatment tumor but was on therapy for 66 weeks and achieved a partial response.
DOI:
10.1158/2159-8290.CD-13-0617
